Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NEXTSTELLIS | Mayne Group | N-214154 RX | 2021-04-15 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
nextstellis | New Drug Application | 2023-05-11 |
Expiration | Code | ||
---|---|---|---|
DROSPIRENONE / ESTETROL, NEXTSTELLIS, MAYNE PHARMA | |||
2026-04-15 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Drospirenone / Estetrol, Nextstellis, Mayne Pharma | |||
7732430 | 2025-03-02 | DP | U-3152 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Contraception | D003267 | — | — | — | — | — | — | 2 | 2 |
Drug common name | Estetrol |
INN | estetrol |
Description | Estetrol is a 3-hydroxy steroid that is 17beta-estradiol which has been substituted at the 15alpha and 16alpha positions by two additional hydroxy groups. It is a natural estrogen produced exclusively during pregnancy by the fetal liver. It has a role as an estrogen, an estrogen receptor agonist, a human metabolite, a human xenobiotic metabolite and an oral contraceptive. It is a 3-hydroxy steroid, a 17beta-hydroxy steroid, a 16alpha-hydroxy steroid, a 15alpha-hydroxy steroid and a steroid hormone. It derives from a hydride of an estrane. |
Classification | Small molecule |
Drug class | - |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O |
PDB | — |
CAS-ID | 15183-37-6 |
RxCUI | — |
ChEMBL ID | CHEMBL1230314 |
ChEBI ID | — |
PubChem CID | 27125 |
DrugBank | DB12235 |
UNII ID | ENB39R14VF (ChemIDplus, GSRS) |